Market Place
Sourcing Support
Syndax Unveils Q1 2026 Financials And Business Update
30 Apr 2026 //
FIRSTWORD PHARMA
Syndax To Unveil Q1 2026 Financial Results, Host Conference Call
24 Apr 2026 //
GLOBENEWSWIRE
Syndax Pharma Awards Inducement Grants Under Nasdaq Listing Rule
03 Apr 2026 //
GLOBENEWSWIRE
Syndax Pharma Reports Inducement Grants per NASDAQ LR 5635(c)(4)
04 Mar 2026 //
GLOBENEWSWIRE
Syndax To Unveil Q4 & Full Year 2025 Financials, Host Conference
19 Feb 2026 //
GLOBENEWSWIRE
Syndax Issues Inducement Grants per Nasdaq Listing Rule
04 Feb 2026 //
GLOBENEWSWIRE
Syndax Unveils 2025 Financials, Updates At J.P. Morgan Conference
12 Jan 2026 //
GLOBENEWSWIRE
Syndax To Present At 8Th Evercore Healthcare Conference
01 Dec 2025 //
GLOBENEWSWIRE
Syndax Pharma Discloses Inducement Grants Per NASDAQ LR
05 Nov 2025 //
GLOBENEWSWIRE
Syndax Reports Q3 2025 Financials And Business Update
03 Nov 2025 //
GLOBENEWSWIRE
Syndax Announces Participation In November Investor Conferences
30 Oct 2025 //
GLOBENEWSWIRE
Syndax To Unveil Q3 2025 Financial Results, Host Conference
27 Oct 2025 //
GLOBENEWSWIRE
Syndax Pharma Discloses Inducement Grants Per NASDAQ LR
03 Oct 2025 //
GLOBENEWSWIRE
Syndax Pharma Disclose Inducement Grants per Nasdaq LR 5635(c)(4)
05 Sep 2025 //
GLOBENEWSWIRE
Syndax Announces Participation in September Investor Conferences
26 Aug 2025 //
GLOBENEWSWIRE
Syndax Pharmaceuticals Grants Inducements Under Nasdaq Listing
06 Aug 2025 //
GLOBENEWSWIRE
Syndax Reports Q2 2025 Financial Results, Updates on Business
04 Aug 2025 //
GLOBENEWSWIRE
Syndax`s Q2 2025 Financial Results and Call on August 4
28 Jul 2025 //
GLOBENEWSWIRE
Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq
02 Jul 2025 //
GLOBENEWSWIRE
NeuroPace Announces Strategic CFO Transition
24 Jun 2025 //
GLOBENEWSWIRE
Syndax presents new Revuforj® data at EHA 2025
12 Jun 2025 //
GLOBENEWSWIRE
Syndax Pharma Reports Inducement Grants Under NASDAQ 5635(c)(4)
05 Jun 2025 //
GLOBENEWSWIRE
Syndax Announces Participation in June Investor Conferences
29 May 2025 //
GLOBENEWSWIRE
Syndax Pharma Appoints Dr. Nicholas Botwood as Head of R&D & CMO
12 May 2025 //
GLOBENEWSWIRE
Syndax Announces Participation in May Investor Conferences
08 May 2025 //
GLOBENEWSWIRE
Syndax Publishes Revumenib Data in mNPM1 AML in Blood
07 May 2025 //
GLOBENEWSWIRE
Syndax Reports Q1 2025 Financial Results and Business Update
05 May 2025 //
GLOBENEWSWIRE
Syndax Pharma Reports Inducement Grants Under NASDAQ LR 5635(c)(4)
02 May 2025 //
GLOBENEWSWIRE
Syndax to Announce Q1 2025 Financial Results on May 5
28 Apr 2025 //
GLOBENEWSWIRE
Syndax Pharma Reports Inducement Grants Under NASDAQ LR 5635(c)(4)
04 Apr 2025 //
GLOBENEWSWIRE
Syndax to Participate in Stifel 2025 Oncology Forum
02 Apr 2025 //
GLOBENEWSWIRE
Syndax Pharma Reports Inducement Grants Under NASDAQ LR 5635(c)(4)
05 Mar 2025 //
GLOBENEWSWIRE
Syndax Announces Participation in March Investor Conferences
25 Feb 2025 //
GLOBENEWSWIRE
Syndax to Announce Q4 & Full Year 2024 Results on March 3
24 Feb 2025 //
GLOBENEWSWIRE
Syndax Pharma Reports Inducement Grants Under NASDAQ LR 5635(c)(4)
04 Feb 2025 //
PR NEWSWIRE
Syndax Announces Participation in February Investor Conferences
30 Jan 2025 //
PR NEWSWIRE
Syndax Highlights 2025 Milestones At J.P. Morgan Conference
13 Jan 2025 //
PR NEWSWIRE
Syndax Announce Presentation at 43rd Annual J.P. Morgan Conference
07 Jan 2025 //
PR NEWSWIRE
Syndax Pharma Reports Inducement Grants Under NASDAQ LR 5635(c)(4)
03 Jan 2025 //
PR NEWSWIRE
New combination treatments promising for blood cancers
11 Dec 2024 //
REUTERS
Syndax`s Positive Revuforj® Data in Relapsed/Refractory mNPM1 AML
09 Dec 2024 //
PR NEWSWIRE
Syndax`s Revuforj® Data Positive In Acute Leukemias Trials
07 Dec 2024 //
PR NEWSWIRE
Syndax Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
03 Dec 2024 //
PR NEWSWIRE
Syndax Announces Participation at Citi 2024 Healthcare Conference
27 Nov 2024 //
PR NEWSWIRE
Onco360 Selected As Specialty Pharmacy Partner For Revuforj
20 Nov 2024 //
GLOBENEWSWIRE
For 2nd time in three months, Syndax wins FDA nod for a new drug
18 Nov 2024 //
FIERCE PHARMA
Syndax strikes $350M funding deal with Royalty Pharma
06 Nov 2024 //
FIERCE PHARMA
Syndax to Host ASH Investor Event Dec 9, 2024
05 Nov 2024 //
PR NEWSWIRE
Syndax Reports Q32024 Financial Results & Provides Business Update
05 Nov 2024 //
PR NEWSWIRE
Syndax & Royalty Pharma Enter $350M Niktimvo™ Royalty Deal
04 Nov 2024 //
PR NEWSWIRE
Syndax Announces Participation in November Investor Conferences
01 Nov 2024 //
PR NEWSWIRE
Syndax Reports Inducement Grants Under NASDAQ Rule 5635(c)(4)
01 Nov 2024 //
PR NEWSWIRE
Syndax To Announce Q3 2024 Results On Nov 5 2024
29 Oct 2024 //
PR NEWSWIRE
Syndax Reports Inducement Grants Under NASDAQ LR 5635(c)(4)
04 Oct 2024 //
PR NEWSWIRE
Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Rule
06 Sep 2024 //
PR NEWSWIRE
Incyte, Syndax bag FDA approval for Niktimvo in graft-versus-host disease
15 Aug 2024 //
FIERCE PHARMA
Incyte And Syndax’s Niktimvo™ Approved By FDA For Chronic GVHD Treatment
14 Aug 2024 //
BUSINESSWIRE
Syndax Publishes AUGMENT-101 Trial Data On Revumenib In Leukemia
12 Aug 2024 //
PR NEWSWIRE
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule
05 Aug 2024 //
PR NEWSWIRE
Syndax Reports Q2 2024 Results And Provides Business Update
01 Aug 2024 //
PR NEWSWIRE
